Helus Pharma Inc.
HELP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001833141
In the last 90 days, Helus Pharma Inc. insiders filed 8 open-market purchases and 0 sales; 99 institutions reported holding it in 13F filings for Q2 2026, worth $197.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Helus Pharma Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 8 filings
- 4 insiders, $8.42M in total
- Open-market sells
- 0 filings
- Insiders trading
- 4
- Net value
- +$8.42M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Helus Pharma Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| So Eric H. L. | Director | 4,713,014 | Oct 1, 2026 | 4 |
| Cavers Greg | Chief Financial Officer | 3,000Indirect | Oct 1, 2026 | 1 |
| Glavine Paul | Chief Growth Officer | 4,750,191 | Oct 1, 2026 | 5 |
| Halstead Michael | Chief Executive Officer | 168,568 | Sep 21, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 (view filing)8:13 PM ET | Sep 29 | 2 days | Cavers GregChief Financial Officer | PPurchase | +3.00K | $12.91 | +$38.7K | New position3.00K after | |
| Sep 21, 2026 (view filing)5:07 PM ET | Sep 21 | Same day | Halstead MichaelChief Executive Officer | PPurchase | +100.0K | $13.47 | +$1.35M | +145.8%168.6K after | |
| Sep 11, 2026 (view filing)9:04 AM ET | Sep 8 | 3 daysLate | Glavine PaulChief Growth Officer | PPurchase | +100.0K | $12.47 | +$1.25M | +2.4%4.27M after | Duplicate filing |
| Sep 11, 2026 (view filing)9:03 AM ET | Sep 8 | 3 daysLate | Glavine PaulChief Growth Officer | PPurchase | +100.0K | $12.47 | +$1.25M | +2.4%4.27M after | |
| Sep 11, 2026 (view filing)9:01 AM ET | Sep 8 | 3 daysLate | So Eric H. L.Executive Chair | PPurchase | +100.0K | $12.39 | +$1.24M | +2.3%4.47M after | |
| Sep 10, 2026 (view filing)6:21 AM ET | Sep 4 | 6 daysLate | So Eric H. L.Executive Chair | PPurchase | +100.0K | $12.09 | +$1.21M | +2.3%4.37M after | |
| Sep 10, 2026 (view filing)6:19 AM ET | Sep 3 | 7 daysLate | Glavine PaulChief Growth Officer | PPurchase | +100.0K | $11.78 | +$1.18M | +2.5%4.17M after | |
| Sep 9, 2026 (view filing)5:47 PM ET | Sep 1 | 8 daysLate | So Eric H. L.Executive Chair | PPurchase | +95.0K | $11.81 | +$1.12M | +2.3%4.27M after | |
| Sep 9, 2026 (view filing)11:03 AM ET | Aug 31 | 9 daysLate | Glavine PaulChief Growth Officer | PPurchase | +90.0K | $11.59 | +$1.04M | +2.3%4.07M after |